Click Here To View
Latest Diabetes Articles
Popular Diabetes Articles
Highly Recommended Diabetes Articles
Send a link to this page to your friends and colleagues.
Compared with other basal insulins, French researchers suggest that insulin detemir (Levemir) may offer a “better reproducibility.” In addition, it may also reduce the risk of hypoglycemia and lead patients to titrate their insulin doses more easily.
Levemir is the latest basal insulin to receive FDA approval. In previous studies, the researchers say that Levemir was associated with “significantly less within-subjects variability for the pharmacodynamic endpoints than both NPH insulin and [Lantus].” They add, “Day-to-day within-subject variations in plasma glucose were significantly lower with insulin detemir than with human NPH insulin.”
Similar results have been reported in patients with type 2.
“Nightly eight-hour plasma glucose recordings showed a smoother and more stable profile with insulin detemir than with NPH insulin,” say the researchers. “In patients with type 1 diabetes, the combination of insulin detemir with mealtime [NovoLog] provides a smoother and more stable profile with lower postprandial plasma glucose levels than the combination of NPH insulin with regular human insulin before each meal.”
The risk of hypoglycemia was also significantly lower with Levemir than with NPH insulin.
—Diabetes and Metabolism, September 2005
Apr 1, 2006